Geode Capital Management’s Quoin Pharmaceuticals QNRX Stock Holding History

Geode Capital Management’s Portfolio QNRX Stock Details QNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3	Closed	-$6K	–	5039
2022 Q2	$6K	Hold	3	–	–	﹤0.01%	5003
2022 Q1	$19K	Buy	+3	New	+$22.4K	﹤0.01%	4933
2021 Q4	–	Sell	-2	Closed	-$240K	–	4990
2021 Q3	$240K	Buy	+2	New	+$195K	﹤0.01%	4360
2021 Q2	–	Hold	0	–	–	–	4681

Other funds holding QNRX

GSC

Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management's QNRX Position: Q3 2022 in Review

Geode Capital Management sold out of Quoin Pharmaceuticals (QNRX) in Q3 2022, closing a stake of 3 shares — an estimated $6K sold.

Geode Capital Management first reported a position in QNRX in Q3 2021 and held it in 3 quarters. The position peaked at $240K in Q3 2021. 6 funds tracked by Wall St. Rank hold QNRX as of Q3 2022.

Geode Capital Management reported no remaining Quoin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Geode Capital Management sold 3 Quoin Pharmaceuticals shares in Q3 2022, an estimated $6K.
Geode Capital Management first reported a position in Quoin Pharmaceuticals in Q3 2021 and held it in 3 quarters.
Geode Capital Management's Quoin Pharmaceuticals position peaked at $240K in Q3 2021.
6 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q3 2022.

Based on Geode Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.